Effectiveness of indacaterol/glycopyrronium/mometasone for refractory asthmatic cough after switching from inhaled corticosteroid/long-acting β₂-agonist therapy.

ABSTRACT:

Background

Cough is a major symptom in poorly or partially controlled asthma, which persists despite treatment, thus impairing quality of life.

Objectives

The primary objective was to demonstrate the superiority of medium-dose indacaterol, glycopyrronium, and mometasone furoate (IND/GLY/MF) over high-dose inhaled corticosteroids (ICS)/long-acting β₂-agonists (LABA) in adult asthma patients with cough refractory to medium-dose ICS/LABA.

Methods

In this multicenter, randomized, open-label, parallel-group study, 118 patients were randomized to receive either IND/GLY/MF or high-dose ICS/LABA (fluticasone/vilanterol [FF/VI] or budesonide/formoterol [BUD/FM]) for 8 weeks. Efficacy was measured by the Japanese version of the Leicester Cough Questionnaire at week 8

SUBMITTER: Niimi A 

PROVIDER: S-EPMC12528903 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature